Search results for "pair [nucleon]"

showing 10 items of 68 documents

The hMTH1 paradox: antioxidants recommended in cancer?

2014

Summary Activated Ras GTPase signalling is a critical driver of oncogenic transformation and malignant disease. Cellular models of RAS-dependent cancers have been used to identify experimental small-molecules, such as SCH51344, but their molecular mechanism of action remains generally enigmatic. Here, using a chemical proteomic approach we identify the target of SCH51344 as the human mutT homologue MTH1, a nucleotide pool sanitising enzyme. Loss-of-function of MTH1 impaired growth of KRAS tumour cells whereas MTH1 overexpression mitigated sensitivity toward SCH51344. Searching for more drug-like inhibitors, we identified the kinase inhibitor crizotinib as a nanomolar suppressor of MTH1 acti…

MalePyridinesMEDLINEDNA repairAntineoplastic AgentsAntioxidantesSaludBiologyBioinformaticsstereoselectivityBiochemistryArticleText miningNeoplasmsmedicineAnimalsHumanscancerMolecular BiologyProtein Kinase Inhibitorscrizotinibbusiness.industryNucleotidesCancerdrugCell BiologyCáncermedicine.diseasePhosphoric Monoester HydrolasesMTH1DNA Repair EnzymesPyrazolesFemalebusiness
researchProduct

Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy

2011

Type 1 diabetes, if poorly controlled, leads to skeletal muscle atrophy, decreasing the quality of life. We aimed to search highly responsive genes in diabetic muscle atrophy in a common diabetes model and to further characterize associated signaling pathways. Mice were killed 1, 3, or 5 wk after streptozotocin or control. Gene expression of calf muscles was analyzed using microarray and protein signaling with Western blotting. We identified translational repressor protein REDD1 (regulated in development and DNA damage responses) that increased seven- to eightfold and was associated with muscle atrophy in diabetes. The diabetes-induced increase in REDD1 was confirmed at the protein level. …

Malemedicine.medical_specialtyMAP Kinase Signaling SystemPhysiologyEndocrinology Diabetes and MetabolismFOXO1P70-S6 Kinase 1MyostatinBiologyMiceRandom Allocation03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineAnimalsRNA MessengerPhosphorylationMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathwayOligonucleotide Array Sequence Analysis030304 developmental biology0303 health sciencesForkhead Box Protein O1Gene Expression ProfilingTOR Serine-Threonine KinasesUbiquitinationForkhead Transcription FactorsOrgan SizeMyostatinProtein ubiquitinationMuscle atrophyMuscular AtrophyDNA Repair EnzymesDiabetes Mellitus Type 1EndocrinologyGene Expression Regulationbiology.proteinPhosphorylationmedicine.symptomProto-Oncogene Proteins c-akt030217 neurology & neurosurgeryTranscription FactorsAmerican Journal of Physiology-Endocrinology and Metabolism
researchProduct

Measurement of the mass of the W boson using direct reconstruction at √s = 183 GeV

1999

From data corresponding to an integrated luminosity of 53.5 pb(-1) taken during the 183 GeV run in 1997, DELPHI has measured the W mass from direct reconstruction of WW --> lq (q) over bar and WW --> q (q) over bar q (q) over bar events. Combining these channels, a value of m(w) = 80.238 +/- 0.154(stat) +/- 0.035(syst) +/- 0.035(fsi) +/- 0.021 (LEP) GeV/c(2) is obtained, where fsi denotes final state interaction. Combined with the W mass obtained by DELPHI from the WW production cross-section and with the direct measurement at 172 GeV this leads to a measured value of m(w) = 80.270 +/- 0.137(stat) +/- 0.031(syst) +/- 0.030(fsi) +/- 0.021(LEP)GeV/c(2), in good agreement with the Standard Mod…

Nuclear and High Energy PhysicsParticle physicsEINSTEIN CORRELATIONSCLUSTERING-ALGORITHMElectron–positron annihilationMathematicsofComputing_GENERALCOLOR DIPOLE MODEL01 natural sciencesComputer Science::Digital LibrariesPartícules (Física nuclear)LuminosityStandard ModelPHYSICSEVENTSNuclear physicsLEP20103 physical sciencesMONTE-CARLO PROGRAM[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]ANNIHILATION010306 general physicsDELPHIPhysicsAnnihilation010308 nuclear & particles physicsE(+)E(-) INTERACTIONSTheoryofComputation_GENERALLARGE ELECTRON POSITRON COLLIDERMONTE-CARLO PROGRAM; PAIR CROSS-SECTION; COLOR DIPOLE MODEL; E(+)E(-) INTERACTIONS; EINSTEIN CORRELATIONS; CLUSTERING-ALGORITHM; ANNIHILATION; PHYSICS; EVENTS; LEP2PARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIComputer Science::Mathematical SoftwarePARTICLE PHYSICSProduction (computer science)Física nuclearPAIR CROSS-SECTIONParticle Physics - ExperimentBar (unit)
researchProduct

Sensitivity enhancement in pulse EPR distance measurements

2004

Established pulse EPR approaches to the measurement of small dipole-dipole couplings between electron spins rely on constant-time echo experiments to separate relaxational contributions from dipolar time evolution. This requires a compromise between sensitivity and resolution to be made prior to the measurement, so that optimum data are only obtained if the magnitude of the dipole-dipole coupling is known beforehand to a good approximation. Moreover, the whole dipolar evolution function is measured with relatively low sensitivity. These problems are overcome by a variable-time experiment that achieves suppression of the relaxation contribution by reference deconvolution. Theoretical and exp…

Nuclear and High Energy PhysicsProtein ConformationBiophysicsAnalytical chemistryBiochemistrySensitivity and Specificitylaw.inventionlawspin labelingSensitivity (control systems)protein structurepair correlation functionElectron paramagnetic resonanceCouplingSpinsChemistryPulsed EPRRelaxation (NMR)Time evolutionElectron Spin Resonance SpectroscopyPhotosystem II Protein ComplexReproducibility of ResultsSignal Processing Computer-AssistedELDORCondensed Matter PhysicsComputational physicsDeconvolutionEPRAlgorithms
researchProduct

Extra-pair paternity and male characteristics in the pied flycatcher

1995

The pied flycatcher (Ficedula hypoleuca) is sexually dichromatic with extreme variation in male plumage coloration. The benefit for males of having black plumage is controversial, and few studies have found evidence for a sexual selection benefit of being black rather than brown. However, blacker males may be better able to achieve extra-pair fertilizations (EPFs), which may be an important component of sexual selection. We studied the role of EPFs in sexual selection in the pied flycatcher by establishing a set-up where two males with different back coloration (blacker vs browner) bred simultaneously near each other. DNA fingerprinting analysis revealed that 11% of offspring resulted from …

OffspringEcologymedia_common.quotation_subjectOutbreeding depressionFicedulaZoologyBiologybiology.organism_classificationAnimal ecologyPlumageSexual selectionAnimal Science and ZoologyExtra-pair copulationReproductionEcology Evolution Behavior and Systematicsmedia_commonBehavioral Ecology and Sociobiology
researchProduct

Correction:Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrom…

2020

Lynch syndrome (LS) results from pathogenic variants in the mismatch repair (MMR) genes and is the most common hereditary cancer syndrome, affecting an estimated 1 in 300 individuals. Pathogenic variants in each of the MMR genes path_MLH1, path_MSH2, path_MSH6, and path_PMS2 result in different risks for cancers in organs including the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas, and upper urinary tract. Accurate estimates of these risks are essential for planning appropriate approaches to the prevention or early diagnosis of cancers but the robustness of previous studies has been limited by factors including retrospective design,1,2 lack of validation in ind…

OncologyMaleColorectal cancer*Lynch syndromePenetranceDNA Mismatch Repair0302 clinical medicineDatabases GeneticMalalties hereditàriesProspective StudiesCàncer*PMS2Genetics (clinical)Mismatch Repair Endonuclease PMS2Cancer0303 health sciencesSex CharacteristicsFactors de risc en les malalties1184 Genetics developmental biology physiologyMLH1Middle Aged16. Peace & justiceLynch syndrome3. Good healthDNA-Binding ProteinsMutS Homolog 2 Proteinsyöpägeenit*MSH2030220 oncology & carcinogenesis*MSH6030211 gastroenterology & hepatologyDNA mismatch repairFemalegeneettiset tekijätMutL Protein Homolog 1Genetic diseasesAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRisk factors in diseasessuolistosyövätMUTATION CARRIERSMLH1Risk AssessmentArticlesukupuoliAge and gender03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLynchin oireyhtymäGene030304 developmental biologyAgedbusiness.industryEndometrial cancerCorrectionnutritional and metabolic diseasesCancer*MLH1MSH6medicine.diseaseColorectal Neoplasms Hereditary NonpolyposisSurvival Analysisdigestive system diseasesMSH2MSH6Lynch syndromePMS2MSH2Mutation3111 BiomedicineikäbusinessOvarian cancer
researchProduct

PMS2: a potential prognostic protein marker in oral squamous cell carcinoma

2020

Background An increase in oral squamous cell carcinoma (OSCC) cases was observed despite the reduction in exposure to classic risk factors. Although the exact cause of this trend remains unknown, epigenetic factors could be contributing to an increased occurrence of these tumors. This study aims to assess the influence of PMS2 protein immunoexpression on the prognosis of patients with OSCC. Material and Methods This study comprised 76 cases of OSCC treated between 2011 and 2016. Immunohistochemical staining for PMS2 was performed. For evaluation, 10 fields per histological section were photographed at a 400x magnification and positively-stained cells were counted with Image J. Mann-Whitney …

Oncologymedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentperiodontal diseaseOral Cancer and Potentially malignant disordersInternal medicineBiomarkers TumormedicinePMS2HumansBasal cellperiodontitisGeneral DentistryUNESCO:CIENCIAS MÉDICASSurvival analysisMismatch Repair Endonuclease PMS2ChemotherapySquamous Cell Carcinoma of Head and NeckProportional hazards modelbusiness.industryResearchMiddle Agedprostate cancerPrognosisImmunohistochemistryProtein markersmeta-analysisstomatognathic diseasesOtorhinolaryngologyHead and Neck NeoplasmsCarcinoma Squamous CellImmunohistochemistryMouth NeoplasmsSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Translationally invariant coupled cluster method in coordinate space for nuclei

2002

We study a formulation of the translationally invariant coupled cluster method in coordinate space for finite nuclei. The new formulation remedies convergence problems that plagued previous calculations in configuration space. The method is applied to light nuclei using semi-realistic central interactions.

PhysicsLight nucleusNuclear and High Energy Physics/dk/atira/pure/subjectarea/asjc/3100/3106Nuclear structureInvariant (physics)Physics and Astronomy(all)Coupled clusterClassical mechanics/dk/atira/pure/subjectarea/asjc/3100Quantum electrodynamicsNuclear binding energyConfiguration spaceCLOSED-SHELL NUCLEI; MODEL-CALCULATIONS; CBF THEORY; DEPENDENT CORRELATIONS; PAIR CORRELATIONS; FINITE SYSTEMS; GROUND-STATE; JASTROW; O-16; Nuclear binding energy; Nuclear model; Nuclear structure; Nucleon-nucleon potential (formulation of translationally invariant coupled cluster method in coordinate space for closed shell nuclei within 0p-shell with use of semi-realistic central nucleon-nucleon interactions)Coordinate spaceGround state
researchProduct

The translationally-invariant coupled cluster method in coordinate space

2000

We study a formulation of the translationally-invariant coupled cluster method in coordinate space. Previous calculations in configuration space showed poor convergence, a problem that the new formulation is expected to remedy. This question is investigated for a system of bosons interacting through the Wigner part of the Afnan-Tang S3 interaction, where previous results exist.

PhysicsNuclear and High Energy Physics/dk/atira/pure/subjectarea/asjc/3100/3106two-body correlationsMANY-BODY TECHNIQUESCiencias FísicasFísica NuclearFinite systemFísica//purl.org/becyt/ford/1.3 [https]Invariant (physics)COUPLED CLUSTER METHODS//purl.org/becyt/ford/1 [https]Classical mechanicsCoupled clustercoupled cluster methodsmany-body techniquesTWO-BODY CORRELATIONSConfiguration spaceCoordinate spaceCiencias ExactasCIENCIAS NATURALES Y EXACTASmany-body techniques; two-body correlations; coupled cluster methods; pair correlations; finite systems; nucleiBoson
researchProduct

Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

2019

Abstract Sustained pulmonary delivery of tobramycin from microparticles composed of drug/polymer nanocomplexes offers several advantages against traditional delivery methods. Namely, in patients with cystic fibrosis, microparticle delivery can protect the tobramycin being delivered from strong mucoadhesive interactions, thus avoiding effects on its diffusion toward the infection site. Polymeric ion-pair complexes were obtained starting from two synthetic polyanions, through impregnation of their solid dissociated forms with tobramycin in aqueous solution. The structure of these polymeric systems was characterized, and their activities were examined against various biofilm-forming Pseudomona…

Pseudomonas aeruginosa infectionpseudomonas aeruginosa infectionsBiocompatibilityCystic FibrosisαPharmaceutical Science02 engineering and technologymedicine.disease_cause030226 pharmacology & pharmacyCystic fibrosisCell Line03 medical and health sciences0302 clinical medicineIon-pair complexmedicineTobramycinHumansPseudomonas InfectionsMicroparticleαβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)chemistry.chemical_classificationDrug CarriersAqueous solutionPseudomonas aeruginosaBiofilms; Cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; Pseudomonas aeruginosa infections; Tobramycin; α; β-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)BiofilmBiofilmPolymerBiofilms; cystic fibrosis artificial mucus (CF-AM); Ion-pair complex; pseudomonas aeruginosa infections; Tobramycin; αβ-Poly-(N-2-hydroxyethyl)-dl-aspartamide (PHEA)021001 nanoscience & nanotechnologymedicine.diseaseAnti-Bacterial AgentsMucuschemistryBiofilmsPseudomonas aeruginosaBiophysicsTobramycinNanoparticlescystic fibrosis artificial mucus (CF-AM)0210 nano-technologyPeptidesmedicine.drug
researchProduct